Identification by RNA-based arbitrarily primed PCR of the involvement of cytochrome c oxidase in the development of resistance to methotrexate

Biochim Biophys Acta. 2000 Feb 28;1495(3):319-26. doi: 10.1016/s0167-4889(99)00159-7.

Abstract

RNA-based arbitrarily primed PCR (RAP-PCR) was used to identify sequences in CHO K1 cells that were differentially expressed upon methotrexate incubation during the development of resistance to this drug. Ten different RAP products were isolated, cloned and sequenced. Among these, we identified one sequence that showed 84% identity with the nucleotide sequence of rat cytochrome c oxidase subunit II, and 90% identity with the amino acid sequence of this protein. This RAP fragment was up-regulated in a dose- and time-dependent manner. The overexpression of cytochrome c oxidase subunit II mRNA as a result of methotrexate incubation was corroborated by quantitative RT-PCR and Northern blot analysis. Incubation of cells with sodium azide, a specific cytochrome c oxidase inhibitor, decreased the number of resistant colonies after methotrexate treatment. Thus, overexpression of cytochrome c oxidase is involved in the development of resistance to methotrexate. These results suggest that sodium azide may be used as a modulator in chemotherapy with methotrexate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antimetabolites, Antineoplastic / pharmacology*
  • CHO Cells
  • Cell Survival / drug effects
  • Cricetinae
  • Drug Interactions
  • Drug Resistance / physiology
  • Electron Transport Complex IV / antagonists & inhibitors
  • Electron Transport Complex IV / genetics
  • Electron Transport Complex IV / metabolism*
  • Enzyme Inhibitors / pharmacology
  • Methotrexate / pharmacology*
  • Polymerase Chain Reaction / methods
  • RNA, Messenger / analysis

Substances

  • Antimetabolites, Antineoplastic
  • Enzyme Inhibitors
  • RNA, Messenger
  • Electron Transport Complex IV
  • Methotrexate